Indeed, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study showed that blocking inflammation with the anti-IL-1β monoclonal antibody canakinumab reduced heart attacks, strokes, and new-onset diabetes among patients with prior myocardial infarction [8]. Here, IL1B is linked to myocardial infarction.